Biperiden Lactate
The lactate salt of biperiden, often formulated for intramuscular or intravenous injection in emergency management of acute drug-induced dystonia or severe Parkinson's symptoms. It acts rapidly to relieve muscle spasm and involuntary movements. This injectable form is particularly useful when oral administration is not feasible.
Peso Molecular
401,5000 g/mol
TPSA
81,00 Ų
Áreas Terapêuticas
Mecanismo de Ação
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
CC(O)C(=O)O.OC(CCN1CCCCC1)(c1ccccc1)C1CC2C=CC1C2
InChI
InChI=1S/C21H29NO.C3H6O3/c23-21(19-7-3-1-4-8-19,11-14-22-12-5-2-6-13-22)20-16-17-9-10-18(20)15-17;1-2(4)3(5)6/h1,3-4,7-10,17-18,20,23H,2,5-6,11-16H2;2,4H,1H3,(H,5,6)
Molecular Formula
C24H35NO4
HBD / HBA
3 / 5
Ligações Rotacionáveis
6
Átomos Pesados
29
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
The lactate salt of biperiden, often formulated for intramuscular or intravenous injection in emergency management of acute drug-induced dystonia or severe Parkinson's symptoms. It acts rapidly to relieve muscle spasm and involuntary movements. This injectable form is particularly useful when oral administration is not feasible.
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
Yes, Biperiden Lactate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201067. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 197083. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="biperiden-lactate"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/biperiden-lactate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/biperiden-lactate/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/biperiden-lactate/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="biperiden-lactate"></drugfyi-drug>